このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PERQDISC従来の実現可能性トライアル。

2026年11月4日 更新者:Spinal Stabilization Technologies

単一レベルのディスコジェネック腰痛の治療におけるPERQDISC人工インプラントのマルチセンター伝統的な実現可能性試験。

This is a traditional feasibility study (TFS) study to evaluate the safety and effectiveness of the PerQdisc. The study is prospective, multicenter, and open label.

After a screening period, qualified participants will be enrolled and treated with the PerQdisc. Patients will not be blinded to their treatment. Participants will then complete the safety follow-up period.

調査の概要

状態

募集

詳細な説明

The proposed investigation is a multicenter, prospective, traditional feasibility study of the PerQdisc. A minimum of N=5 subjects will be enrolled. Subjects will be enrolled in approximately 2 sites. Data analyses including all enrolled subjects meeting specific criteria will be submitted to the FDA to support a pivotal trial and used in trial planning. This study will evaluate the safety and effectiveness of the PerQdisc device in the treatment of single level discogenic back pain caused by degenerative disc disease (DDD) (L1 to L5).

研究の種類

介入

入学 (推定)

5

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Arizona
      • Glendale、Arizona、アメリカ、85308
        • 引きこもった
        • Hope Research Institute
      • Phoenix、Arizona、アメリカ、85032
        • 引きこもった
        • HOPE Research Institute
      • Phoenix、Arizona、アメリカ、85023
        • 募集
        • The CORE Institute
        • コンタクト:
        • 主任研究者:
          • Ali Araghi, DO
      • Scottsdale、Arizona、アメリカ、85251
        • 募集
        • HonorHealth Research & Innovation Institute
        • コンタクト:
        • 主任研究者:
          • Luis Tumialan, MD
    • Florida
      • Miami、Florida、アメリカ、33136
        • 募集
        • University of Miami
        • 主任研究者:
          • Michael Wang, MD
        • コンタクト:
    • Idaho
      • Coeur d'Alene、Idaho、アメリカ、83854
        • 募集
        • Axis Spine Center
        • 主任研究者:
          • Roland Kent, MD
        • コンタクト:
    • Indiana
      • Carmel、Indiana、アメリカ、46032
        • 募集
        • Indiana Spine Group
        • コンタクト:
        • 主任研究者:
          • Paul Kraemer, MD
    • Louisiana
      • Shreveport、Louisiana、アメリカ、71101
        • 募集
        • Spine Institute of Louisiana
        • コンタクト:
        • 主任研究者:
          • Pierce Nunley, MD
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73159
        • 引きこもった
        • SonoSpine

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

22年~70年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Skeletally mature male or female subjects aged 22-70 (inclusive).
  2. Subject has a primary diagnosis of single level discogenic back pain caused by degenerative disc disease (L1 to L5) identified via MRI.
  3. Subject has an intact annulus (as determined by MRI) and endplates (as determined by MRI and X-ray) at the level to be treated.
  4. Subject must have failed to respond to a minimum of 6 months of conservative treatment for their back pain (e.g., physical therapy, medications, injections, ablations, lifestyle changes, etc.).
  5. Subject has a low back pain VAS ≥40 mm (4 cm).
  6. Subject has adequate disc height (≥6mm measured at the center of the disc) at the level to be treated. [As measured by the investigator]
  7. Subject is psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms.
  8. Subject has read and understands the IRB approved informed consent document prior to signing and dating the document and before the initiation of any study-related procedures
  9. Subject is appropriate candidate for the PerQdisc surgical approach [as defined in the surgical technique guide].

Exclusion Criteria:

  1. Subject has symptomatic degenerative disc disease at more than one lumbar level

  2. Subject has had a prior spinal fusion in the lumbar or thoracic intervertebral spaces.

  3. Subject has had a prior SI-joint fusion.

  4. Subject has a spinal cord stimulator.

  5. Subject has had any prior lumbar spine surgery (instrumented or non-instrumented)

  6. Subject has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.

  7. Subject has congenital moderate or severe spinal stenosis or epidural lipomatosis.

  8. Subject has spondylolisthesis (antero- or retrolisthesis) in static X-ray ≥3 mm [measured via neutral lateral x-ray]

  9. Subject has ≥4 mm dynamic spondylolisthesis [measured via flexion/extension x-rays]

  10. Subject has > 20 degree range of motion at the index level [measured via flexion/extension x-rays]

  11. Subject has a history of any invasive malignancy (except non-melanoma skin cancer) unless treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years (in particular, spinal tumors).

  12. Subject has an active systemic infection or infection at the operative site.

  13. Subject has evidence of symptomatic facet joint degeneration or disease where the investigator feels the facet is a major contributor to the subject's pain as diagnosed by injection and/or imaging.

  14. Subject has a known allergy to silicone or barium sulfate.

  15. Subject has been diagnosed with fibromyalgia, hepatitis, rheumatoid arthritis, lupus erythematosus, AIDs, ARC, HIV, or an autoimmune disease that affects the musculoskeletal system.

  16. Subject has been diagnosed with Paget's disease, osteomalacia or any other metabolic bone disease.

  17. Subject has current or recent history (defined ≤ 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) using standard medical definitions of DSM-5

  18. Subject has morbid obesity defined as a body mass index (BMI) > 40.

  19. Subject participated in an investigational drug or another medical device study within the last 30 days prior to surgery.

  20. Subject has Osteoporosis, defined as a T-score ≤ -2.5.

    1. An existing DEXA is allowed if completed within 6 months of subject surgery.
    2. For all subjects without an existing DEXA, the SCORE/MORES will be utilized to screen if a DEXA scan is indicated. If SCORE/MORES value ≥ 6, then a DEXA scan is required.
  21. Female subjects who are pregnant or are trying to become pregnant during the course of the trial.

  22. Subject has diabetes mellitus (Type 1 or 2) requiring daily insulin management.

  23. Subject belongs to a vulnerable population or has a condition such that his/her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally disabled, prisoner, chronic alcohol/ substance abuser)

  24. Subject is currently receiving worker's compensation or is involved in any litigation for medical negligence, trauma, or worker's compensation.

  25. Subject has lumbar scoliosis > 10 degrees at index level.

  26. Subject has a large, rectangular or irregularly shaped Schmorl's node with an associated active inflammatory process (Modic I changes).

  27. Subject has motion of < 3 degrees on pre-operative lateral flexion/extension radiographs at index level.

  28. Subject has opioid medication usage > 60 MME (morphine milligram equivalent)/day or change in opioid prescription within 60 days of surgery.

  29. Subject has a preoperative VAS right or left leg pain score > the preoperative VAS Back score.

  30. Subject has a history of vertebral fractures in the lumbar spine.

  31. Subject has evidence of severe compression of cauda equina.

  32. Subject is on chronic anticoagulation therapy due to a bleeding disorder and is unable to safely stop anticoagulants or has taken anticoagulants within 3 days prior to procedure.

  33. Subject has low back pain (LBP) of non-spinal or unknown etiology.

  34. Subject is unable to undergo X-ray, MRI, or other radiographic assessments, including discography.

  35. Subject has a degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to spinal disease (not at index level), Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis.

  36. Subject has, in the opinion of the investigator, a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the device.

  37. In the opinion of the investigator the subject has a major psychiatric disorder that may interfere with the assessment of the safety or effectiveness of the device.

  38. Subject has myelopathy.

  39. Subject has primarily leg pain with associated nerve root compression, in the opinion of the investigator.

  40. Subject has an annular defect greater than 6mm that extends from the interior of the disc to the outer margin of the annulus as evaluated on MRI.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:PerQdisc

The PerQdisc device is the first in a new category of contained in-situ filled and then cured lumbar spinal implant. The PerQdisc is intended to replace the nucleus pulposus in a single lumbar disc level, preserve motion and alleviate pain. The PerQdisc is a silicone membrane (barrier membrane) configured to be filled with a room temperature vulcanizing silicone (RTVS) that will cure within minutes, resulting in a final shape that conforms to the nucleus space created by the surgical removal of the diseased or damaged nucleus pulposus.

PerQdisc Artificial Implant

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Clinical Composite Success
時間枠:6 Months

Clinical composite success is defined as improvement in pain and absence of qualified safety events.

6 Months

二次結果の測定

結果測定
メジャーの説明
時間枠
ODI
時間枠:6 Months

ODI 15-point responder at Month 6

6 Months
VAS Back
時間枠:6 Months

VAS Back pain 20mm responder at Month 6

6 Months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年1月10日

一次修了 (推定)

2027年9月30日

研究の完了 (推定)

2030年3月31日

試験登録日

最初に提出

2025年2月28日

QC基準を満たした最初の提出物

2025年2月28日

最初の投稿 (実際)

2025年3月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • DISCPAIN1 TFS

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する